$CRYM
Cryomass Technologies, Inc.

2023 Q3 Form 10-Q Financial Statement

#000121390023069520 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $470.0K $550.0K
YoY Change -5.38% -40.65%
% of Gross Profit
Research & Development $13.24K
YoY Change 869.82%
% of Gross Profit
Depreciation & Amortization $13.08K $13.08K
YoY Change -40.12% -40.1%
% of Gross Profit
Operating Expenses $1.373M $6.275M
YoY Change 9.53% 343.05%
Operating Profit -$1.373M -$6.275M
YoY Change 9.53% 343.05%
Interest Expense $109.3K $82.60K
YoY Change 330.15% -682.52%
% of Operating Profit
Other Income/Expense, Net -$80.56K -$87.09K
YoY Change -417.01% 514.42%
Pretax Income -$1.450M -$6.360M
YoY Change 18.04% 344.63%
Income Tax
% Of Pretax Income
Net Earnings -$1.454M -$6.362M
YoY Change 18.35% 344.75%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.03
Diluted Earnings Per Share -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 206.2M shares 205.3M shares
Diluted Shares Outstanding 207.4M shares 205.2M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00K $316.3K
YoY Change -99.68% -85.55%
Cash & Equivalents $9.485K $316.3K
Short-Term Investments
Other Short-Term Assets $210.0K $162.1K
YoY Change 53.69% 142.58%
Inventory
Prepaid Expenses $190.8K $140.4K
Receivables
Other Receivables
Total Short-Term Assets $222.1K $478.4K
YoY Change -93.2% -78.78%
LONG-TERM ASSETS
Property, Plant & Equipment $736.1K $749.2K
YoY Change 110.58% 114.32%
Goodwill
YoY Change
Intangibles $114.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $850.2K $880.3K
YoY Change -91.31% -90.99%
TOTAL ASSETS
Total Short-Term Assets $222.1K $478.4K
Total Long-Term Assets $850.2K $880.3K
Total Assets $1.072M $1.359M
YoY Change -91.78% -88.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.730M $1.591M
YoY Change 40.08% 46.09%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $386.5K $0.00
YoY Change
Long-Term Debt Due $230.0K $222.6K
YoY Change
Total Short-Term Liabilities $1.980M $1.814M
YoY Change 60.3% 66.53%
LONG-TERM LIABILITIES
Long-Term Debt $2.430M $2.300M
YoY Change 21.5% 859.88%
Other Long-Term Liabilities $80.00K
YoY Change
Total Long-Term Liabilities $2.510M $2.300M
YoY Change 25.5% 859.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.980M $1.814M
Total Long-Term Liabilities $2.510M $2.300M
Total Liabilities $4.490M $4.113M
YoY Change 38.8% 209.59%
SHAREHOLDERS EQUITY
Retained Earnings -$48.43M -$46.97M
YoY Change 44.99% 46.0%
Common Stock $210.0K $205.8K
YoY Change 3.71% 2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.418M -$2.755M
YoY Change
Total Liabilities & Shareholders Equity $1.072M $1.359M
YoY Change -91.78% -88.7%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$1.454M -$6.362M
YoY Change 18.35% 344.75%
Depreciation, Depletion And Amortization $13.08K $13.08K
YoY Change -40.12% -40.1%
Cash From Operating Activities -$870.0K -$999.1K
YoY Change -1.69% -25.28%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $35.50K
YoY Change -159.07% -126.24%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$20.00K -$35.50K
YoY Change -40.93% -73.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 590.0K 686.9K
YoY Change -68.29% 938.4%
NET CHANGE
Cash From Operating Activities -870.0K -999.1K
Cash From Investing Activities -20.00K -35.50K
Cash From Financing Activities 590.0K 686.9K
Net Change In Cash -300.0K -347.7K
YoY Change -131.86% -75.27%
FREE CASH FLOW
Cash From Operating Activities -$870.0K -$999.1K
Capital Expenditures $20.00K $35.50K
Free Cash Flow -$890.0K -$1.035M
YoY Change 4.57% -13.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Gross Profit
GrossProfit
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
us-gaap Revenues
Revenues
usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56155
dei Entity Registrant Name
EntityRegistrantName
CRYOMASS TECHNOLOGIES INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5051728
dei Entity Address Address Line1
EntityAddressAddressLine1
1001 Bannock Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 612
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80204
dei Local Phone Number
LocalPhoneNumber
303-416-7208
dei City Area Code
CityAreaCode
303
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
206218637 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
316267 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2016057 usd
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
21788 usd
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
21788 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
140351 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
128651 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
478406 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2166496 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
749225 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
525855 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1190000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
131117 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3980582 usd
CY2023Q2 us-gaap Assets
Assets
1358748 usd
CY2022Q4 us-gaap Assets
Assets
7862933 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1591006 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1288465 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
222630 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1813636 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1288465 usd
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
178817 usd
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
2120872 usd
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
2000000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
4113325 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3288465 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
205768637 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
205768637 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
202651205 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
202651205 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
205769 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
202652 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44011514 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43163579 usd
CY2022Q4 crym Common Stock To Be Issued
CommonStockToBeIssued
219765 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46971860 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39011528 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2754577 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4574468 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1358748 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7862933 usd
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
723455 usd
CY2022Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
466422 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1491720 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
801652 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
446149 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
238432 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
786045 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
533781 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
104497 usd
CY2022Q2 us-gaap Legal Fees
LegalFees
688194 usd
us-gaap Legal Fees
LegalFees
403239 usd
us-gaap Legal Fees
LegalFees
2146451 usd
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
144336 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21831 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
268865 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
43663 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13238 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1365 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13361 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18487 usd
CY2023Q2 crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
3653043 usd
crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
3653043 usd
CY2023Q2 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1190000 usd
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1190000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
6274718 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1416244 usd
us-gaap Operating Expenses
OperatingExpenses
7806273 usd
us-gaap Operating Expenses
OperatingExpenses
3544034 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6274718 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1416244 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7806273 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3544034 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
82602 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
35235 usd
us-gaap Interest Expense
InterestExpense
136263 usd
us-gaap Interest Expense
InterestExpense
71258 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4486 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
21061 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-17796 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
32569 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87088 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14174 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-154059 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38689 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-6361806 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1430418 usd
us-gaap Profit Loss
ProfitLoss
-7960332 usd
us-gaap Profit Loss
ProfitLoss
-3582723 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6361806 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1430418 usd
us-gaap Net Income Loss
NetIncomeLoss
-7960332 usd
us-gaap Net Income Loss
NetIncomeLoss
-3582723 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
205232785 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
200596549 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
204881096 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
200164004 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13524320 usd
CY2022Q1 crym Common Stock Issued Value For Current Period Service
CommonStockIssuedValueForCurrentPeriodService
240625 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
140815 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2152305 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11753455 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66151 usd
CY2022Q2 crym Common Stock Issued Value For Current Period Service
CommonStockIssuedValueForCurrentPeriodService
240626 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
69095 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1430418 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
10698909 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4574468 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
65626 usd
CY2023Q1 crym Common Stock Issued Vested Rs Us Value For Current Period Services
CommonStockIssuedVestedRSUsValueForCurrentPeriodServices
50000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
62972 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1598526 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3154540 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20112 usd
CY2023Q2 crym Common Stock Issued Vested Rs Us Value For Current Period Services
CommonStockIssuedVestedRSUsValueForCurrentPeriodServices
79920 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
173631 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
179026 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6361806 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2754577 usd
us-gaap Net Income Loss
NetIncomeLoss
-7960332 usd
us-gaap Net Income Loss
NetIncomeLoss
-3582723 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13036 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
62500 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
268866 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
43663 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1412 usd
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1190000 usd
crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
3653043 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
401044 usd
us-gaap Share Based Compensation
ShareBasedCompensation
209910 usd
crym Common Stock Issued For Vested Rs Us For Current Period Service
CommonStockIssuedForVestedRSUsForCurrentPeriodService
129920 usd
crym Stockbased Compensation For Vested Rs Us For Current Period Services
StockbasedCompensationForVestedRSUsForCurrentPeriodServices
236603 usd
crym Common Stock Issued For The Current Period Services
CommonStockIssuedForTheCurrentPeriodServices
85738 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
11700 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-690542 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
55964 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-793360 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2337450 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2968424 usd
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
618831 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124586 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
49236 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19325 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49236 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-762742 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66151 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
80208 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
686896 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
686896 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146359 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1699790 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2016057 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5772839 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
316267 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2188032 usd
crym Purchase Of Property And Equipment On Credit
PurchaseOfPropertyAndEquipmentOnCredit
246577 usd
crym Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable
DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable
179026 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Nature of the Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>CryoMass Technologies Inc. develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. </span>The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes. Building on this technology, CryoMass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The first functional commercial unit, known as a CryoSift Separator™, has been installed at the premises of an operating partner, pursuant to a license and lease arrangement to deploy multiple trichome separation units California and other locations. It has successfully transitioned from beta testing and entered into readiness for commercial-level processing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s principal office is located at 1001 Bannock St., Suite 612, Denver, CO 80204, and its telephone number is 303-416-7208. The Company’s website is www.cryomass.com. Information appearing on the website is not incorporated by reference into this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryomass Technologies Inc is the parent company to wholly-owned subsidiaries Cryomass LLC, Cryomass California LLC, and 1304740 B.C. Unlimited Liability Company dba Cryomass Canada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 22, 2021, the Company entered into an Asset Purchase Agreement with Cryocann USA Corp, a California corporation (“Cryocann”), pursuant to which Company acquired substantially all the assets of Cryocann. The acquired assets included the patented cryogenic process titled “System and method for cryogenic separation of plant material” (US patent #10,864,525) for the reduction of biomass and efficient isolation, collection and preservation of delicate resin glands (trichomes) <span>of </span>harvested of hemp and cannabis, and potentially other high value trichome-rich plants</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, we were granted an additional patent for our process from the Chinese Intellectual Property Office. In April 2022, we were granted another patent # 3,064,896 from the Canadian Intellectual Property Office. We currently are taking steps to gain further protection for our intellectual property through the European Union Intellectual Property Office and other international jurisdictions.</p>
CY2021Q2 us-gaap Agricultural Related Inventory Plant Material
AgriculturalRelatedInventoryPlantMaterial
10864525 usd
CY2021Q3 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
3064896 usd
CY2023Q2 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
1335230 usd
CY2023Q2 us-gaap Cash
Cash
316267 usd
us-gaap Retail Land Sales Estimated Cost Of Major Improvements
RetailLandSalesEstimatedCostOfMajorImprovements
4200000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6600000 usd
crym Cash For Operating Activities
CashForOperatingActivities
2337450 usd
us-gaap Malpractice Loss Contingency Claims Incurred Net
MalpracticeLossContingencyClaimsIncurredNet
7960332 usd
CY2023Q2 crym Accumulated Deficits
AccumulatedDeficits
46971860 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to determining the fair value of the assets acquired and liabilities assumed in acquisition, determining the useful lives and potential impairment of long-lived assets and potential impairment of goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2023Q2 us-gaap Other Loans Payable
OtherLoansPayable
686896 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts. Aside from this, the Company does not believe it is exposed to any unusual credit risk.</p>
CY2022Q2 crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
usd
crym Income Taxes Description
IncomeTaxesDescription
In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy will be to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit will be recognized in the condensed consolidated financial statements.
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
2290085 shares
crym Unvested Of Shares Restricted Stock Potentially Dilutive Securities Outstanding
UnvestedOfSharesRestrictedStockPotentiallyDilutiveSecuritiesOutstanding
1258982 shares
crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
usd
CY2023Q2 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
749225 usd
CY2022Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
525855 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28607 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5400 usd
CY2023Q2 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
749225 usd
CY2022Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
525855 usd
CY2023Q2 us-gaap Depreciation
Depreciation
13077 usd
us-gaap Depreciation
Depreciation
23207 usd
CY2023Q2 us-gaap Goodwill Gross
GoodwillGross
0 usd
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
1190000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1190000 usd
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1190000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4230482 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
446322 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
-3653043 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
131117 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4181246 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
200664 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3980582 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
131260 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
245659 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21833 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43663 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
34206 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
68412 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
28499 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
131117 usd
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6600000 usd
CY2021Q4 crym Net Realizable Shares
NetRealizableShares
3600000 shares
CY2022Q1 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
618831 usd
CY2023Q2 us-gaap Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
686896 usd
CY2023Q2 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.12 pure
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.25
us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
The fair value of the Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions at the dates of issuance, including the Company stock price ($0.13 for April subscription agreements, $0.09 for May subscription agreements, $0.12 for June subscription agreement), exercise price ($0.25), term (4 years), historical volatility (153%), and risk-free rate (3.8% for April subscription agreements, 3.6% and 3.7% for May subscription agreements for Mario Gobbo and a private investor, respectively, 4.0% for June subscription agreement).
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
179026 usd
crym Fair Value Of Promissory Notes
FairValueOfPromissoryNotes
507870 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
179026 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
522319 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
13345 usd
CY2022Q3 us-gaap Securities Loaned Or Sold Under Agreements To Repurchase Fair Value Disclosure
SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseFairValueDisclosure
2000000 usd
CY2022Q3 us-gaap Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent
FinancingReceivableModificationToTotalFinancingReceivablesExcludingAccruedInterestPercent
0.12 pure
us-gaap Deferred Sales Inducement Cost Amortization Expense Accrued Interest
DeferredSalesInducementCostAmortizationExpenseAccruedInterest
20000 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
175000 usd
us-gaap Related Party Tax Expense Effect Of Change In Allocation Methodology
RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology
54128 usd
CY2023Q2 us-gaap Investment Maturity Date
InvestmentMaturityDate
2025-04-17
us-gaap Financing Receivable Modification To Total Financing Receivables Excluding Accrued Interest Percent
FinancingReceivableModificationToTotalFinancingReceivablesExcludingAccruedInterestPercent
0.12 pure
us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.25
CY2022Q1 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
the Company issued 458,334 shares of common stock for a total dollar value of $160,417 and accrued an additional $80,208 in common stock to be issued at a later date for a total dollar value of $240,625 in exchange for services. The Company also issued 550,000 shares of common stock for 2021 management performance bonuses, 185,529 shares of common stock for director compensation, and 1,000,000 shares of common stock for 2020 RSU grants vesting in January 2022, all of which were expensed over the RSU grant vesting period, incurring $140,815 of expense during the first quarter of 2022.
CY2022Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
220500 shares
CY2022Q2 crym Common Stock Shares
CommonStockShares
687501 shares
CY2022Q2 crym Common Stock In Exchange For Services
CommonStockInExchangeForServices
240626 shares
CY2022Q2 crym Issuance Of Common Stock Shares
IssuanceOfCommonStockShares
1000000 shares
CY2022Q2 crym Share Based Payment Arrangement Noncash Expense
ShareBasedPaymentArrangementNoncashExpense
69095 usd
CY2023Q1 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
the Company issued 62,500 shares of common stock for a total dollar value of $21,875 for prior period services, 187,500 shares of common stock for a total dollar value of $65,626 for current period services, 777,932 shares of common stock for a total dollar value of $50,000 for vested RSUs for current period services, and 1,100,000 shares of common stock for a total dollar value of $197,890 for vested RSUs for prior period services.
CY2023Q2 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
the Company issued 187,500 shares of common stock for current period services, as follows: 62,500 shares were issued at $0.091 per share for a total dollar value of $5,687, 62,500 shares were issued at $0.0909 per share for a total dollar value of $5,681, and 62,500 shares were issued at $0.1399 per share for a total dollar value of $8,744, all related to compensation to a consultant. The Company issued 802,000 shares of common stock for vested RSUs for current period services, as follows: 550,000 shares were issued at $0.098 per share for a total dollar value of $53,900, 187,000 shares were issued at $0.0995 per share for a total dollar value of $18,607, 10,000 shares were issued at $0.1088 per share for a total dollar value of $1,088, and 55,000 shares were issued at $0.115 per share for a total dollar value of $6,325, all relating to employee compensation.
CY2023Q2 crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
79920 usd
crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
327810 usd
CY2022Q2 crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
317000 usd
crym Fair Value Of Rs Us Vested
FairValueOfRSUsVested
1165600 usd
crym Unrecognized Stock Based Compensation
UnrecognizedStockBasedCompensation
416205 usd
crym Unrecognized Stock Based Compensation
UnrecognizedStockBasedCompensation
274241 usd
CY2022Q2 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
usd
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
2540550 shares
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.25
CY2021Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
73950000 shares
CY2021 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.4
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2023Q2 crym Common Stock To Be Issued
CommonStockToBeIssued
usd
us-gaap Revenues
Revenues
usd
us-gaap Gross Profit
GrossProfit
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
200164004 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
200596549 shares
CY2023Q1 crym Common Stock Issued For Prior Period Services
CommonStockIssuedForPriorPeriodServices
usd
CY2023Q1 crym Common Stock Issued For Vested Rs Us Value For Prior Period Services
CommonStockIssuedForVestedRSUsValueForPriorPeriodServices
usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
usd
crym Loss On Impairment Of Intangible Assets
LossOnImpairmentOfIntangibleAssets
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
crym Common Stock Issued For Vested Rs Us For Current Period Service
CommonStockIssuedForVestedRSUsForCurrentPeriodService
usd
crym Stockbased Compensation For Vested Rs Us For Current Period Services
StockbasedCompensationForVestedRSUsForCurrentPeriodServices
usd
crym Common Stock Issued For The Current Period Services
CommonStockIssuedForTheCurrentPeriodServices
usd
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3584807 usd
crym Purchase Of Property And Equipment On Credit
PurchaseOfPropertyAndEquipmentOnCredit
usd
crym Debt Discount Recognized From Warrants Issued In Conjunction With Notes Payable
DebtDiscountRecognizedFromWarrantsIssuedInConjunctionWithNotesPayable
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001533030

Files In Submission

Name View Source Status
0001213900-23-069520-index-headers.html Edgar Link pending
0001213900-23-069520-index.html Edgar Link pending
0001213900-23-069520.txt Edgar Link pending
0001213900-23-069520-xbrl.zip Edgar Link pending
crym-20230630.xsd Edgar Link pending
f10q0623ex10-1_cryomass.htm Edgar Link pending
f10q0623ex10-2_cryomass.htm Edgar Link pending
f10q0623ex31-1_cryomass.htm Edgar Link pending
f10q0623ex31-2_cryomass.htm Edgar Link pending
f10q0623ex32-1_cryomass.htm Edgar Link pending
f10q0623ex32-2_cryomass.htm Edgar Link pending
f10q0623_cryomass.htm Edgar Link pending
crym-20230630_cal.xml Edgar Link unprocessable
crym-20230630_def.xml Edgar Link unprocessable
crym-20230630_lab.xml Edgar Link unprocessable
crym-20230630_pre.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0623_cryomass_htm.xml Edgar Link completed